PL3199165T3 - Sposoby i kompozycje do specyficznego hamowania kras przez asymetryczne dwuniciowe rna - Google Patents

Sposoby i kompozycje do specyficznego hamowania kras przez asymetryczne dwuniciowe rna

Info

Publication number
PL3199165T3
PL3199165T3 PL17160821.9T PL17160821T PL3199165T3 PL 3199165 T3 PL3199165 T3 PL 3199165T3 PL 17160821 T PL17160821 T PL 17160821T PL 3199165 T3 PL3199165 T3 PL 3199165T3
Authority
PL
Poland
Prior art keywords
kras
compositions
methods
stranded rna
specific inhibition
Prior art date
Application number
PL17160821.9T
Other languages
English (en)
Inventor
Bob Dale Brown
Original Assignee
Dicerna Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/005214 external-priority patent/WO2010033225A2/en
Priority claimed from US12/642,264 external-priority patent/US20100173973A1/en
Priority claimed from US12/642,371 external-priority patent/US8513207B2/en
Priority claimed from US12/704,256 external-priority patent/US20100249214A1/en
Application filed by Dicerna Pharmaceuticals, Inc. filed Critical Dicerna Pharmaceuticals, Inc.
Publication of PL3199165T3 publication Critical patent/PL3199165T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/342—Hemimers, i.e. of the type ====----
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL17160821.9T 2009-04-03 2010-04-05 Sposoby i kompozycje do specyficznego hamowania kras przez asymetryczne dwuniciowe rna PL3199165T3 (pl)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US16657809P 2009-04-03 2009-04-03
US16655909P 2009-04-03 2009-04-03
US17427909P 2009-04-30 2009-04-30
US17430609P 2009-04-30 2009-04-30
US18381809P 2009-06-03 2009-06-03
US18381509P 2009-06-03 2009-06-03
US18473509P 2009-06-05 2009-06-05
PCT/US2009/005214 WO2010033225A2 (en) 2008-09-22 2009-09-17 Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
US25781009P 2009-11-03 2009-11-03
US25782009P 2009-11-03 2009-11-03
US28592509P 2009-12-11 2009-12-11
US12/642,264 US20100173973A1 (en) 2008-12-18 2009-12-18 Extended dicer substrate agents and methods for the specific inhibition of gene expression
US12/642,371 US8513207B2 (en) 2008-12-18 2009-12-18 Extended dicer substrate agents and methods for the specific inhibition of gene expression
US12/642,404 US20100184841A1 (en) 2008-12-18 2009-12-18 Extended dicer substrate agents and methods for the specific inhibition of gene expression
US12/704,256 US20100249214A1 (en) 2009-02-11 2010-02-11 Multiplex dicer substrate rna interference molecules having joining sequences
US30926610P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
PL3199165T3 true PL3199165T3 (pl) 2022-09-05

Family

ID=42828984

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17160821.9T PL3199165T3 (pl) 2009-04-03 2010-04-05 Sposoby i kompozycje do specyficznego hamowania kras przez asymetryczne dwuniciowe rna

Country Status (13)

Country Link
US (5) US8372816B2 (pl)
EP (3) EP3199165B1 (pl)
JP (1) JP6010458B2 (pl)
KR (1) KR101791702B1 (pl)
CN (3) CN102575254B (pl)
AU (1) AU2010232410B2 (pl)
CA (1) CA2757613C (pl)
DK (2) DK3199165T3 (pl)
ES (2) ES2628144T3 (pl)
HU (1) HUE059432T2 (pl)
PL (1) PL3199165T3 (pl)
PT (1) PT3199165T (pl)
WO (1) WO2010115206A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
CN102575254B (zh) * 2009-04-03 2015-03-04 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
US20150025122A1 (en) * 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US9200326B2 (en) * 2009-12-07 2015-12-01 Arkray, Inc. Probe for detecting polymorphism in disease-related gene and use of the probe
WO2012053741A2 (ko) * 2010-10-22 2012-04-26 성균관대학교산학협력단 Rna 간섭을 유도하는 핵산 분자 및 그 용도
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
ES2897565T3 (es) 2011-10-18 2022-03-01 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina y uso de los mismos
EP3272868A1 (en) * 2012-05-02 2018-01-24 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat kras-related diseases
US10125362B2 (en) 2012-05-22 2018-11-13 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
CA2878314A1 (en) 2012-07-16 2014-01-23 Kyowa Hakko Kirin Co., Ltd. Rnai pharmaceutical composition for suppressing expression of kras gene
KR102205278B1 (ko) 2013-03-14 2021-01-22 다이서나 파마수이티컬, 인크. 음이온성 약제를 제형화하는 방법
PL3444350T3 (pl) 2013-07-03 2022-03-21 Dicerna Pharmaceuticals, Inc. Sposoby i kompozycje do specyficznego hamowania alfa-1 antytrypsyny przez dwuniciowy rna
KR101670254B1 (ko) * 2014-07-09 2016-10-28 서울대학교산학협력단 목적 유전자의 발현 억제 특이성이 증가된 siRNA 분자
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CA2968336C (en) 2014-12-17 2021-11-23 Proqr Therapeutics Ii B.V. Construct for site directed editing of an adenosine nucleotide in target rna
CN108699556B (zh) 2015-11-16 2023-02-17 奥利克斯医药有限公司 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性
US11180759B2 (en) 2016-01-19 2021-11-23 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
EP3405576A4 (en) 2016-01-19 2019-09-18 The University of North Carolina at Chapel Hill METHOD AND COMPOSITIONS WITH RNA INTERFERENCE FOR KRAS INHIBITION
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
CA3022874A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
MA45470A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
CN105858567A (zh) * 2016-04-15 2016-08-17 北京华绿生物科技有限公司 食用菌菌瓶的扣盖稳定器、食用菌菌瓶压盖设备
CN109477103A (zh) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
CN107164379B (zh) * 2016-08-18 2020-06-02 广州市锐博生物科技有限公司 用于抑制VEGFA靶基因mRNA表达的寡核酸分子及其成套组合物
EP3507366B1 (en) 2016-09-01 2020-10-07 ProQR Therapeutics II B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
EP3752615B1 (en) * 2018-02-12 2025-08-27 Lonza Sales AG Methods and compositions for macrophage polarization
CN112020557B (zh) 2018-03-27 2025-02-11 罗切斯特大学 用于假尿苷化的核酸分子
AU2019252529A1 (en) * 2018-04-13 2020-10-01 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US20220154189A1 (en) 2019-03-29 2022-05-19 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
US20220177890A1 (en) * 2019-04-10 2022-06-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hybrid nucleic acid switches
WO2021076574A2 (en) * 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物
CN112980840A (zh) * 2019-12-17 2021-06-18 南京大学 用于癌症治疗的多靶向siRNA
CA3169550A1 (en) * 2020-04-07 2021-10-14 Chad PECOT Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras
CN111534520A (zh) * 2020-05-27 2020-08-14 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用
KR102379204B1 (ko) * 2020-12-18 2022-03-24 이화여자대학교 산학협력단 유전자 침묵 활성이 증가된 핵산 분자 및 이의 이용
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0641212A4 (en) * 1992-05-14 1997-05-21 Ribozyme Pharm Inc PROCESS AND REAGENT FOR PREVENTING THE DEVELOPMENT OF CANCER.
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
EP0843019A3 (en) * 1996-11-08 2002-10-09 Kyowa Medex Co., Ltd. Method for determination of specific nucleic acid sequence, and a reagent therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
CN1608131A (zh) * 2001-10-26 2005-04-20 里伯药品公司 治疗胰腺癌的药物
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
CA2542835A1 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20050176045A1 (en) * 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
EP2121925A2 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
JP2010529834A (ja) * 2007-05-21 2010-09-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌遺伝子の発見のための組成物および方法
DK2193140T3 (en) * 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
CA2704737A1 (en) * 2007-09-18 2009-09-03 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
CN101381779B (zh) * 2008-10-21 2011-06-08 广州益善生物技术有限公司 kRas基因突变的检测探针、液相芯片及其检测方法
CN102575254B (zh) * 2009-04-03 2015-03-04 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
CA2878314A1 (en) * 2012-07-16 2014-01-23 Kyowa Hakko Kirin Co., Ltd. Rnai pharmaceutical composition for suppressing expression of kras gene

Also Published As

Publication number Publication date
EP2414374A4 (en) 2013-09-25
WO2010115206A3 (en) 2010-11-25
EP2414374A2 (en) 2012-02-08
US20200318118A1 (en) 2020-10-08
CN103555722B (zh) 2016-08-31
DK3199165T3 (da) 2022-07-11
CA2757613C (en) 2023-10-17
CN102575254B (zh) 2015-03-04
PT3199165T (pt) 2022-07-13
CA2757613A1 (en) 2010-10-07
JP2012531888A (ja) 2012-12-13
AU2010232410A1 (en) 2011-10-27
HUE059432T2 (hu) 2022-11-28
WO2010115206A2 (en) 2010-10-07
US20130123342A1 (en) 2013-05-16
US11447777B2 (en) 2022-09-20
US20180044680A1 (en) 2018-02-15
KR101791702B1 (ko) 2017-10-30
EP3199165A1 (en) 2017-08-02
KR20120034610A (ko) 2012-04-12
US8372816B2 (en) 2013-02-12
US10752899B2 (en) 2020-08-25
AU2010232410B2 (en) 2016-11-17
ES2628144T3 (es) 2017-08-01
ES2921573T3 (es) 2022-08-29
CN104651362A (zh) 2015-05-27
EP4124657A3 (en) 2023-05-03
US9200284B2 (en) 2015-12-01
US20110021604A1 (en) 2011-01-27
CN103555722A (zh) 2014-02-05
JP6010458B2 (ja) 2016-10-19
US20150057337A1 (en) 2015-02-26
DK2756845T3 (en) 2017-06-12
US9809819B2 (en) 2017-11-07
CN102575254A (zh) 2012-07-11
EP3199165B1 (en) 2022-06-08
EP4124657A2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
HUE059432T2 (hu) Módszerek és kompozíciók a kras aszimmetrikus kettõs szálú RNS által történõ specifikus gátlására
ZA200908342B (en) Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
IL225672A0 (en) Methods and compositions for polymerase inhibition
PT2341943T (pt) Composições e métodos para a inibição específica de expressão génica por dsrna que possui modificações
PT3587579T (pt) Métodos e composições para a inibição específica de beta-catenina por rna de filamento duplo
EP2633046A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 GENES
SG2014005318A (en) Compositions and methods for inhibition of the jak pathway
EP2462230A4 (en) METHOD AND COMPOSITIONS FOR TARGETED GENE MODIFICATION
PL2719699T3 (pl) Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
IL219094A (en) Process for making 2sglt and 2sglt inhibitors manufactured using them
IL217370A0 (en) Novel nucleic acid prodrugs and methods of use thereof
IL209196A (en) A crystalline form of posaconazole
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
SMT202100325T1 (it) Metodi e composizioni per l’inibizione specifica della glicolato ossidasi (hao1) mediante rna a doppio filamento
ZA201106577B (en) Compounds and compositions for cognition-enhancement,methods of making,and methods of treating
IL208374A0 (en) Double-stranded lipid-modified rna having high rna interference effect
ZA201304509B (en) Water clarification composition and process
ZA201006971B (en) Methods and compositions for production of acetaldehyde
IL218967A0 (en) Phenyloxadiazole derivatives as pgds inhibitors
EP2370415A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH
ZA201304275B (en) Water clarification composition and process
ZA201103179B (en) Compositions and methods of use for soluble thrombomodulin variants
IL215486A0 (en) Compositions of cholinesterase inhibitors
EP2376498A4 (en) NEW PANCRATISTATIN C-1 AND 7-DEOXYPANCRATISTATIN ANALOGUES AND METHOD FOR THEIR PREPARATION
AU2013359069A1 (en) Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA